Morgan Keegan Leaves HealthSouth Outperform Rating, $25.50 PT Unchanged (HLS)

Morgan Keegan left its HealthSouth HLS Outperform rating and $25.50 price target unchanged in a research report published today. In the report, Morgan Keegan states, "Last month, HealthSouth announced that fourth quarter discharges were up 5.3% and net revenues per discharge rose 2.5%-2.7%. Combined with strong expense control, we raised our EPS estimate from $0.36 and $0.44. We will update our 2011 model based on how these revenue and expense trends have continued." Shares of HealthSouth were at $22.35 in after hours trading at the time of posting, reflecting no change from Friday's market close.